JP2019518460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518460A5 JP2019518460A5 JP2018565336A JP2018565336A JP2019518460A5 JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5 JP 2018565336 A JP2018565336 A JP 2018565336A JP 2018565336 A JP2018565336 A JP 2018565336A JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5
- Authority
- JP
- Japan
- Prior art keywords
- engineered
- composition
- regulatory
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022021158A JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351104P | 2016-06-16 | 2016-06-16 | |
| US62/351,104 | 2016-06-16 | ||
| PCT/US2017/037794 WO2017218850A1 (en) | 2016-06-16 | 2017-06-15 | Engineered treg cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Division JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518460A JP2019518460A (ja) | 2019-07-04 |
| JP2019518460A5 true JP2019518460A5 (https=) | 2020-07-27 |
Family
ID=60663377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565336A Withdrawn JP2019518460A (ja) | 2016-06-16 | 2017-06-15 | 操作されたＴｒｅｇ細胞 |
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190322983A1 (https=) |
| EP (1) | EP3472305A4 (https=) |
| JP (2) | JP2019518460A (https=) |
| CN (1) | CN109415698A (https=) |
| AU (1) | AU2017285319A1 (https=) |
| CA (1) | CA3027546A1 (https=) |
| MA (1) | MA45498A (https=) |
| WO (1) | WO2017218850A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12098202B2 (en) * | 2016-10-10 | 2024-09-24 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| GB201714718D0 (en) | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| EP3820509A1 (en) | 2018-07-09 | 2021-05-19 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| KR20210125509A (ko) * | 2019-02-01 | 2021-10-18 | 케이에스큐 세러퓨틱스 인코포레이티드 | 개선된 면역요법을 위한 유전자-조절 조성물 및 방법 |
| CA3146013A1 (en) | 2019-07-09 | 2021-01-14 | The Children's Mercy Hospital | Engineered regulatory t cells |
| WO2021154882A1 (en) * | 2020-01-27 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Hdac6-inhibited human regulatory t cells |
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| KR20250169635A (ko) | 2023-01-23 | 2025-12-03 | 메디치니쉐 호흐슐레 하노버 | 항-entpd3 키메라 항원 수용체 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4669343A1 (en) | 2023-02-24 | 2025-12-31 | Medizinische Hochschule Hannover | CHIMERIC ANTIGEN RECIPIENT |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
| EP2167647A2 (en) * | 2007-06-13 | 2010-03-31 | La Jolla Institute For Allergy And Immunology | Regulatory t cells and methods of making and using same |
| US8658159B2 (en) * | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
| ES2928000T3 (es) * | 2014-06-06 | 2022-11-14 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
| AU2015276131A1 (en) * | 2014-06-17 | 2016-11-17 | Cellectis | CD123 specific multi-chain chimeric antigen receptor |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
-
2017
- 2017-06-15 CN CN201780037655.8A patent/CN109415698A/zh active Pending
- 2017-06-15 CA CA3027546A patent/CA3027546A1/en active Pending
- 2017-06-15 WO PCT/US2017/037794 patent/WO2017218850A1/en not_active Ceased
- 2017-06-15 EP EP17814140.4A patent/EP3472305A4/en not_active Withdrawn
- 2017-06-15 MA MA045498A patent/MA45498A/fr unknown
- 2017-06-15 JP JP2018565336A patent/JP2019518460A/ja not_active Withdrawn
- 2017-06-15 AU AU2017285319A patent/AU2017285319A1/en not_active Abandoned
- 2017-06-15 US US16/310,668 patent/US20190322983A1/en not_active Abandoned
-
2022
- 2022-02-15 JP JP2022021158A patent/JP2022058995A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518460A5 (https=) | ||
| Chatzileontiadou et al. | The many faces of CD4+ T cells: immunological and structural characteristics | |
| Lopes et al. | The immune microenvironment in multiple myeloma: friend or foe? | |
| Takamura et al. | Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors | |
| Titov et al. | Knowns and unknowns about CAR-T cell dysfunction | |
| Trzonkowski et al. | Ex vivo expansion of CD4+ CD25+ T regulatory cells for immunosuppressive therapy | |
| Dwyer et al. | Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype | |
| Wang et al. | Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells | |
| Chen et al. | TNF-α: an activator of CD4+ FoxP3+ TNFR2+ regulatory T cells | |
| Rudak et al. | MAIT cell-mediated cytotoxicity: Roles in host defense and therapeutic potentials in infectious diseases and cancer | |
| Bahri et al. | Ectonucleotidase CD38 demarcates regulatory, memory-like CD8+ T cells with IFN-γ-mediated suppressor activities | |
| Sierra et al. | Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation | |
| Pieper et al. | Peripheral and Site‐Specific CD 4+ CD 28null T Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics | |
| KR20210093908A (ko) | Ny-eso-1 t 세포 수용체 및 이의 사용 방법 | |
| Hefazi et al. | Regulatory T cell therapy of graft-versus-host disease: advances and challenges | |
| JP2018524987A5 (https=) | ||
| WO2013192215A1 (en) | Compositions and methods for diminishing an immune response | |
| Fu et al. | Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
| CN112292400A (zh) | 对白介素-23受体特异的嵌合抗原受体 | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? | |
| Bernasconi et al. | Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies | |
| Käser et al. | Porcine regulatory T cells: mechanisms and T-cell targets of suppression | |
| Gramatica et al. | EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes | |
| Khoud et al. | Acute myeloid leukemia: is it T time? | |
| Lin et al. | Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis |